Teva and Cephalon faced the €60.5 million antitrust fine, after both companies were found to be actively suppressing the existence of cheaper medicine.
The Oxford and AstraZeneca vaccine trial gave an accidental half-dose to 3,000 people - but this mistake is the reason the vaccine acted as 90% efficient.
Rachel Thrasher, Research Fellow at the Global Development Policy Center in Boston, says this time is different and the TRIPS Council knows it - the COVID-19 vaccine needs to be freely accessible to all countries.
Today (20 November) Pfizer and BioNTech are sending their drug for approval to the FDA, meaning that the most vulnerable Americans could get the vaccine in December.
Eight days after the Pfizer vaccine results (90% effective) brought collective hope to the world, the Moderna vaccine has proven to be 95% effective at fighting COVID-19.
While the US and UK sealed their BioNTech and Pfizer vaccine deals within 24 hours of the new results, the European Commission took 3 days longer to secure their larger order of 300 million doses.
Rex Clements, CEO at Centrient Pharmaceuticals, discusses how the upcoming EU Pharma Strategy can prevent shortages and strengthen Europe’s manufacturing base, especially for antibiotics.
Researchers from the Health Economics Unit and University of Leeds looked at the cost of treating strokes and found that the drugs prescribed are so effective they save the NHS money.
Here, we talk to Professor Trevor Jones at the European Medical Cannabis Association (EUMCA) about storing CBD, clinical trials post-Brexit and the UK-US trade deal.
Josep Figueras and Anna Sagan from the European Observatory on Health Systems and Policies focus here on antimicrobial resistance and ponder whether or not this could be the next big pandemic.
Renata Mala, PharmD, Chairman of Purely Plant GmbH, underlines the importance of ensuring high and reproducible quality when it comes to medicinal cannabis.
